Page 4 - Diabetes

Why jamun seed powder is called a superfood for managing diabetes

Jamun seed powder contains jamboline and jambosine that help regulate blood sugar, support pancreatic function, and may aid in diabetes prevention if used correctly

Understanding gestational diabetes: Why early detection, awareness matter

Despite common misconceptions, gestational diabetes can affect healthy women of any age or body type. Often symptomless, it frequently goes undiagnosed-putting both mother and child at risk

Does your job involve meeting people? It may raise diabetes risk: Study

A 14-year study of nearly 3 million people found that emotional strain in public-facing roles may increase type 2 diabetes risk by up to 47 per cent

Stem cell breakthrough: New therapy raises hopes of curing type 1 diabetes

A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope for long-term freedom from injections

Abbott, MSD join hands to distribute key diabetic drug across India

Abbott to distribute MSD's sitagliptin portfolio-Januvia, Janumet, Janumet XR-in India, targeting deeper reach in the ₹950-1,000 crore diabetes drug segment

That 'healthy' juice habit? It might be messing with your metabolism

Think juice is better than soda? A large new study shows even 100% fruit juice raises diabetes risk, urging people to eat whole fruits instead

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower

Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade

It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Can the '2 per 20' rule really help stabilise blood sugar without exercise?

Research shows that light walking for 2 minutes after every 20 minutes of sitting may significantly lower post-meal blood sugar levels

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

Insulin's century-old legacy still stands tall amid new diabetes drugs

Despite the rise of GLP-1s and oral therapies, insulin remains vital for millions, particularly those with type 1 diabetes and other insulin-dependent conditions

Patent loss led to rise in prescriptions of new generation diabetes drugs

Experts say 85% price drop in empagliflozin expected to boost SGLT2 usage; SGLT-2 class of drugs account for 25-30% of all diabetes prescriptions

What is Type 5 diabetes? IDF recognises malnutrition-linked condition

Long overlooked and often misdiagnosed, Type 5 diabetes, caused by malnutrition-linked reduced insulin production, has finally gained official recognition

Hit the gym! Building muscles may cut diabetes risk by 44%, genes no bar

Muscle up, sugar down: A new study has found individuals with high muscle strength have a 44% lower risk of developing type 2 diabetes, irrespective of their genetic predisposition to the disease

Anti-obesity drug Mounjaro now in India: Know details here

India gets yet another diabetes and obesity management drug- a popular competitor of Ozempic that has been available in India. Watch the video to know the details.

Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..